BMJ Open Association between forced expiratory volume in 1 s and relapse-free survival in operable non-small cell lung cancer: a prospective cohort study with propensity score overlap weighting

Shaoping Wu,¹ Siqian Fu,^{1,2} Jeffrey William Ripley-Gonzalez,¹ Ni Cui,¹ Yang Du,^{2,3} Karl Sylvester,^{4,5} Baiyang You,^{1,2} Ning Xu,⁶ Jing Cheng,⁷ Yaoshan Dun,^{1,2,8} Suixin Liu ¹

To cite: Wu S, Fu S, Ripley-Gonzalez JW, *et al.* Association between forced expiratory volume in 1 s and relapse-free survival in operable non-small cell lung cancer: a prospective cohort study with propensity score overlap weighting. *BMJ Open* 2024;**14**:e085076. doi:10.1136/ bmjopen-2024-085076

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2024-085076).

SW and SF contributed equally.

Received 17 February 2024 Accepted 15 November 2024

Check for updates

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Suixin Liu; liusuixin@csu.edu.cn and Dr Yaoshan Dun; dunyaoshan@csu.edu.cn

ABSTRACT

Objectives Investigate the correlation between the percentage of predicted forced expiratory volume in 1 s (FEV1%pred) and survival outcomes, namely relapse-free survival (RFS) and overall survival (OS), in patients diagnosed with operable early-stage non-small cell lung cancer (NSCLC).

Design Prospective observational study.

Setting Clinical settings in Xiangya Hospital, Central South University, Hunan, China.

Participants From November 2014 to December 2019, 775 operable patients with NSCLC, median age 58 years (IQR 13) with 40.6% women, were consecutively enrolled and underwent preoperative FEV1 assessment. All participants were evaluated using the FEV1%pred assessment. Subsequent treatments and operative interventions followed established protocols for NSCLC.

Results During the follow-up, which lasted a median of 40 months (range 1-85 months) and continued until December 2021, 202 patients either relapsed or died. Optimal FEV1%pred cut-off was identified using receiver operating characteristic analysis. Results revealed 110 and 71 relapses and deaths per 1000 person-years for patients with FEV1 values of < 82% pred and $\ge 82\%$ pred, respectively. Cox proportional hazards models, adjusted for demographics, medical history and surgery characteristics with propensity score overlap weighting, revealed the significant impact of lower FEV1%pred on decreased RFS and OS. An FEV1%pred less than 82% displayed a significant association with decreased RFS (weighted HR, 1.55; 95% CI, 1.14 to 2.09; p=0.007) and OS (weighted HR, 1.50; 95% Cl, 1.01 to 2.23; p=0.04). **Conclusions** Lower FEV1%pred values notably correlate with compromised RFS and OS in individuals operable for early-stage NSCLC, suggesting that FEV1%pred may serve as a valuable tool in evaluating and managing long-term recurrence risk in patients with early-stage NSCLC.

Trial registration number ChiCTR2100048120.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This study adopted the propensity score overlap weighting technique to mitigate the impact of extreme propensities on model outcomes, which is a standardised and published methodology.
- ⇒ This study exclusively enrolled patients who underwent preoperative cardiopulmonary exercise testing, which could introduce selection bias.

BACKGROUND

and In 2020, lung cancer was the leading cause of cancer-related deaths worldwide, resulting data in approximately 1.8 million fatalities and 2.2 million new diagnoses. The vast majority of these cases, ranging from 80% to 85%, are categorised as non-small cell lung cancer ≥ (NSCLC).¹ For individuals diagnosed with early-stage NSCLC, operative lung resection is widely regarded as the most effective onco-logical treatment option. However, patients g with lung cancer remain at a significant risk of relapse and death within a 5-year span post-diagnosis.² Up to 32-66% of patients with NSCLC relapse or die after surgery,³ and about 83% of relapses are metastatic, which significantly affects the long-term survival of patients. Identifying those patients with NSCLC who are at a heightened risk of **G** disease recurrence or mortality might help **3** with clinical decision-making and personalised intervention strategies.

British Thoracic Society recommends that suitability for surgery should be assessed based on age, cardiovascular health, nutritional and exercise status and respiratory function.⁴ The forced expiratory volume in 1 s (FEV1) stands as a critical clinical physiological parameter, indicating the volume of air

Protected by copyright, including for uses related to text

exhaled during the initial second of a forced exhalation following maximal effort.⁵ FEV1 is one of the most useful parameters in pulmonary function tests for the assessment of patients with lung resection, which is convenient and non-invasive.⁶ The percentage of predicted FEV1 (FEV1%pred) is derived by dividing the actual FEV1 value by its predicted norm, which is adjusted for age, sex and height.⁷ Recent research increasingly acknowledges FEV1%pred as not only a marker of impaired lung function but also as a potential predictor of perioperative morbidity, particularly in patients with lung cancer.⁸

Despite its emerging significance, there is a scarcity of studies examining the relationship between FEV1%pred and overall survival (OS) in the context of post-lung resection patients, with only four such studies reported to date, vielding inconsistent findings.^{9–12} Three of these studies have identified a correlation between FEV1%pred and OS in patients with lung cancer, although with varying threshold values,¹⁰⁻¹² while one study found no significant link between FEV1%pred and postoperative mortality.⁹ Furthermore, to the best of our knowledge, the association between FEV1%pred and postoperative relapse in patients with NSCLC remains unexplored. Considering the high availability and non-invasive procedure of FEV1%pred detection, investigating the role of FEV1% pred in predicting relapse-free survival (RFS) and OS holds promise and is of clinical significance.

In this prospective observational study, we carried out a relatively large sample size to explore the correlation between FEV1%pred and long-term RFS as well as OS in individuals diagnosed with operable early-stage NSCLC, by adopting propensity score overlap weighting technique to mitigate the impact of extreme propensities.

MATERIALS AND METHODS Study design and participants

This prospective observational research was conducted as a component of the Xiangya Hospital Exercise Testing (X-ET) project.¹³ Individuals with suspected NSCLC who were slated for lung resection and underwent the preoperative FEV1 evaluation were consecutively included in the study between 1 November 2014 and 31 December 2019. In the screening process, individuals with small cell lung cancer, benign tumours, advanced-stage (IIIB and IV) NSCLC, chronic obstructive pulmonary disease (COPD), emphysema and those with a prior history of other malignancies were excluded. Additionally, the study has been registered in the Chinese Clinical Trial Registry with the unique identification number ChiCTR2100048120, and we have adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting our work.

Preoperative FEV1 assessment

The preoperative FEV1 values were measured during preoperative cardiopulmonary exercise testing using the CARDIOVIT system (Schiller Switzerland). To ensure

the equipment quality, daily volume and flow verification were conducted. We established the acceptability and usability criteria for FEV1 and forced vital capacity (FVC) based on the guidelines provided by the American Thoracic Society and the European Respiratory Society.¹⁴

Definition of exposed group and outcomes

We determined the ideal threshold for FEV1%pred as the primary outcome through receiver operating characteristic (ROC) curve analysis and the calculation of the Youden index.¹⁵ Individuals with FEV1%pred values below the designated threshold were categorised into the exposed group. FEV1%pred = (FEV1 observed/FEV1 predicted) × 100. Predicted FEV1 was calculated by the following equations¹⁶: FEV1 predicted = $4.301 \times \text{height}$ (m) – $0.029 \times \text{age}$ (years) – 2.492, male; FEV1 predicted = $3.953 \times \text{height (m)} - 0.025 \times \text{age (years)} - 2.604$, female. FEV1% pred = (FEV1 observed/FEV1 predicted) × 100.

The primary outcome was RFS. Follow-up time referred to the period from the day of lung resection to the incidence of either relapse or death or to 31 December 2021. The secondary outcome was OS. The time-to-death event o extended from enrolment to death from any cause. Verification of relapses and deaths involved a three-pronged approach, which included (1) gathering data from the Residence Registration Office, (2) examining the electronic medical record system and (3) conducting follow-up by contacting the families of the study participants.

Covariates

Age, gender, body mass index and smoking history information were gathered on enrolment. Data concerning tumour histology, clinical stage, type of lung resection and factors that might be associated with RFS and OS were obtained from the electronic medical record system following the surgical procedure.

Sample size

, AI training In this study, given the absence of an exact comparable study, we referenced a similar study to estimate the effect size.¹¹ Based on an estimated HR of 1.5, a desired power of 0.8, and the occurrence of 202 events in our cohort, we used the Cox proportional hazards model to calculate the required sample size. The total estimated sample size needed for the study is approximately 734 participants, sposure groups. To guarantee the accuracy of the proposed model, es is advisable to have at least 10 equivalent enwith this number encompassing both the control and exposure groups.

it is advisable to have at least 10 equivalent events for each adjusted covariate.¹⁷ The presence of 202 observed relapses or deaths in the present study was sufficient for the development of our regression models, allowing for the adjustment of up to 20 covariates. Moreover, we employed the propensity score overlap weighting technique for covariate adjustment, which combines and assigns weights to all covariates as a single regression variable.

BMJ Open: first published as 10.1136/bmjopen-2024-085076 on 20 December 2024. I Enseignement uses 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de l nement Superieur (ABES) đ text and data З ≥ ğ

Statistical analysis

The Shapiro-Wilk test was conducted to assess the normality of continuous variables. Non-normally distributed continuous variables were presented as the median and IQR, while normally distributed continuous variables were described as mean±SD. Categorical variables were reported as counts (percentages). Standardised mean difference (SMD) was used to gauge the balance of individual covariates both before and after applying the propensity score overlap weighting technique.¹⁸ Conventionally, an SMD less than 0.1 is considered adequate for balance.¹⁸ Additionally, a Love plot was created to display covariate balance before and after the weighting.

The propensity score model with covariates was established using the overlap weighting method to mitigate the impact of extreme propensities on model outcomes.¹⁹ Weight assignment in overlap weighting was done based on the probability of individuals belonging to the alternative group.¹⁹

Kaplan-Meier curves were generated for both RFS and OS. To evaluate the statistical significance of the differences between the low and high FEV1%pred groups in the survival curves, the log-rank test was employed. Cox proportional hazards models were used to examine the relationship between FEV1%pred and RFS as well as OS, both before and after adjusting for covariates through propensity score overlap weighting. Furthermore, we calculated both the crude and weighted incidence rates, representing the relapse or mortality rate per 1000 person-years.

The association between FEV1%pred and RFS and OS was internally validated using bootstrapping. Briefly, 1000 bootstrap samples were generated, and the Brier scores, calibration slope and C-index were estimated to assess the Cox proportional hazards models' overall performance, agreement and efficiency in distinguishing patients at high and low risks of relapse and death.²⁰

An examination of interactions was conducted for all covariates (recorded confounding factors), and the E-factor was used to evaluate unmeasured confounders.²¹ Furthermore, predefined subgroup examinations were executed considering birth gender, age, body mass index (BMI and tobacco use status. Propensity scores with overlap weighting were regenerated prior to creating the subgroup model. Considering the risk of type I errors arising from multiple comparisons, the subgroup analyses were regarded as exploratory.

The analysis was conducted using R software (V.4.2.0). We made use of packages such as pROC, PSweight, tableone, cobalt, survival, survminer, fmsb, rms, boot and E-value. Statistical significance was set at p<0.05 (two-sided). The code and relevant references for the statistical analyses are openly accessible on the GitHub repository at this URL: https://github.com/YSDun/ FEV1/blob/101e5cd567302c76d0c79e00cfa4c953 667bbd10/FEV1.Rmd

RESULTS

Characteristics of the participants

Between 1 November 2014 and 31 December 2019, a cohort of 1232 patients with suspected NSCLC underwent preoperative cardiopulmonary exercise testing, with an assessment of their FEV1 values. Following the initial screening process, 775 patients met the eligibility criteria and were enrolled in the study. Meanwhile, 457 individuals were excluded from the study cohort due to benign tumours (n=274), small cell lung cancer (n=13), \neg lung metastases originating from sites other than the lung (n=41), NSCLC at stages IIIB and IV (n=31) and emphysema or COPD (n=98) (figure 1). The median age of the 775 participants was 58 years (IQR, 13 years), with a predominant male representation (59.4%). The **8** online supplemental table 1 displays the characteristics of FEV1, FVC and maximal ventilatory volume. ROC analysis, along with the Youden index, determined an FEV1 value of <82% of the predicted value as the optimal prognostic cut-off in this investigation, as depicted by the ROC curves in online supplemental figure 1. Out of the 775 participants, 234 (30.2%) exhibited an FEV1 below 82% of the predicted value, while 541 (69.8%) demonstrated an FEV1 equal to or greater than 82% of the predicted value. The mean FEV1% pred was 89 (SD, 16).

Male participants, older age, squamous cell lung cancer diagnosis, advanced clinical stages, lower MET levels and a history of smoking were associated with lower FEV1% predicted values. For more details, refer to table 1. Online supplemental figure 1 displays covariate balance before and after propensity score overlap weighting.

The association between FEV1%pred and RFS

Over the study period, 202 patients faced relapse or death. The relapse and death rates were 110 and 71 per 1000 person-years for patients with FEV1 <82% pred and ≥82% pred, respectively (weighted incidence rate difference (95% CI), 39 (25 to 78) events per 1000 personyears). Patients with FEV1 <82%pred had a 1.55-fold higher risk of relapse or death than those with FEV1 $\geq 82\%$ pred (weighted HR (95% CI), 1.55 (1.14 to 2.09)) (table 2). The Kaplan-Meier curve for RFS is presented S in figure 2a.

Several sensitivity analyses were conducted to assess the potential sources of bias that might affect the observed association between FEV1%pred and RFS. First, interaction tests were conducted to assess the influence of **o** the measured covariates. Among these covariates, only & BMI showed a significant interaction (p=0.03), while **3** the remaining covariates did not exhibit significant interactions (all p>0.05) (online supplemental table 2). Prespecified subgroup analyses consistently showed that the association between FEV1%pred and RFS remained stable across the subgroups of older adults, males, individuals with high BMI and those with a history of smoking (figure 3a). The E-value was computed to assess potential interference from unknown confounding factors. The resulting E-value was 2.05, suggesting that residual



Figure 1 Study review from enrolment to analysis. COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; NSCLC, non-small cell lung cancer.

Characteristics of operable patients with early-stage NSCLC, before and after applying propensity score overlap Table 1 weighting

	Crude			Weighted*		
Variable	FEV1 <82%pred (n=234)	FEV1 ≥82%pred (n=541)	Standardised mean difference	FEV1 <82%pred	FEV1 ≥82%pred	Standardised mean difference
Male, n (%)	172 (73.5)	288 (53.2)	0.43	67.1	67.1	<0.001
Age, mean±SD, (years)	59±9	58±9	0.14	58±9	58±9	<0.001
BMI, kg/m ² , mean±SD	23.7±3.1	23.6±2.8	0.04	23.7±3.1	23.7±2.9	<0.001
Ever smoked, n (%)	126 (53.8)	192 (35.5)	0.38	47.8	47.8	<0.001
MET, mean±SD	6.3±1.3	6.6±1.3	0.23	6.5±1.4	6.5±1.3	
Medical history, n (%)						
Hypertension	51 (21.8)	114 (21.1)	0.02	22.2	22.2	<0.001
Dyslipidaemia	30 (12.8)	45 (8.3)	0.15	11.3	11.3	<0.001
T2DM	23 (9.8)	44 (8.1)	0.06	10.0	10.0	<0.001
CAD	43 (18.4)	106 (19.6)	0.03	19.0	19.0	<0.001
Cerebrovascular disease	5 (2.1)	12 (2.2)	0.01	1.6	1.6	<0.001
Chronic bronchitis	13 (5.6)	29 (5.4)	0.01	5.5	5.5	<0.001
Histology, n (%)			0.45			<0.001
Adenomatous	140 (59.8)	431 (79.7)		67.9	67.9	
Squamous	80 (34.2)	86 (15.9)		26.5	26.5	
Others	14 (6.0)	24 (4.4)		5.7	5.7	
Type of lung resections, n (%)			0.26			<0.001
Pneumonectomy	14 (6.0)	11 (2.0)		4.0	4.0	
Lobectomy	210 (89.7)	498 (92.1)		91.6	91.6	
Segmentectomy	5 (2.1)	10 (1.8)		2.1	2.1	
Wedge resection	1 (0.4)	4 (0.7)		0.5	0.5	
No resection ⁺	2 (0.9)	2 (0.4)		0.7	0.7	
Two lung lobes	2 (0.9)	16 (3.0)		1.1	1.1	
Clinical stage, n (%)			0.21			<0.001
0	6 (2.6)	13 (2.4)		2.6	2.6	
	136 (58.1)	364 (67.3)		62.5	62.5	
II	34 (14.5)	71 (13.1)		13.6	13.6	
IIIA	58 (24.8)	93 (17.2)		21.3	21.3	

*After applying overlap weighting, individual data points no longer corresponds to a single entity. Consequently, raw counts for categorical variables are not reported; instead, the percentages are presented.

†Explorative thoracotomy without lung resection.

BMI, body mass index; CAD, coronary artery disease; FEV1, forced expiratory volume in 1 s; MET, metabolic equivalent; NSCLC, non-small cell lung cancer: T2DM, type 2 diabetes mellitus.

confounding could explain the observed relationship between FEV1%pred and RFS if there exists an unmeasured covariate with a relative risk association of at least 2.05 with both impaired FEV1 and relapse or death. However, most other risk factors for relapse or death in patients with NSCLC have an HR of 1.10 or lower,²² which is considerably smaller than 2.05. This suggests that the observed association between FEV1%pred and RFS is less likely to be attributable to an unmeasured confounder.

We performed internal validation through bootstrapping resampling. Our analysis yielded a Brier score of 0.18 (95% CI, 0.17 to 0.19), a calibration slope of 0.79 (95% CI, 0.66 to 0.92) and a C-index of 0.57 (95% CI,

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies 0.52 to 0.62), indicating strong overall performance of the FEV1%pred and RFS regression model (online supplemental table 3).²⁰

The association between FEV1%pred and OS

Over the study duration, 112 participants experienced mortality, with mortality rates of 57 and 38 deaths per 1000 person-years among patients with low and high FEV1%pred, respectively. The weighted incidence rate difference in terms of death between the two groups was 19 (95% CI, 2 to 41) deaths per 1000 person-years. Those with FEV1 <82% predicted had a 1.50 times higher mortality risk than those with FEV1 ≥82% predicted

Crude outcome*

Death (n=112)

Death

Weighted outcomet Relapse or death

Relapse or death (n=202)

Table 2 Association of FEV1%pre

P value

< 0.001

< 0.001

0.007

0.04

ed with RFS and (OS in operable pa	tients with early-stage NS	SCLC
Incidence rate/100 (95% CI)	0 person-years	IRD/1000 person-years (95% CI)	HR (95% CI)
FEV1 <82%pred (n=234)	FEV1 ≥82%pred (n=541)		
119 (94 to 144)	65 (53 to 76)	54 (27 to 82)	1.84 (1.39 to 2.43)
66 (49 to 87)	32 (24 to 41)	34 (14 to 54)	2.09 (1.44 to 3.02)
110 (79 to 141)	71 (47 to 95)	39 (25 to 78)	1.55 (1.14 to 2.09)
57 (38 to 83)	38 (23 to 59)	19 (2 to 41)	1.50 (1.01 to 2.23)
nt the results estimate nt the results estimate D, incidence rate diff	ed before applying pr ed after applying pro erence; NSCLC, non	ropensity score overlap weight pensity score overlap weightir -small cell lung cancer; OS, or	ing to adjust for cova ng to adjust for covari verall survival; RFS, re
01 to 2.23)). The n figure 2b. petween covaria with OS were c p=0.01) (online	Kaplan- on l (N= tes and valu observed pro supple- with	Norwegian (sample size 252), have suggested able prognostic indica gnosis. ^{10 11} Conversely, n stage I NSCLC repo	(N)=148) and D that FEV1%pre ator for predicti a study of Ame rted conflicting

*Crude and weighted outcomes represent variates †Crude and weighted outcomes represent ariates. FEV1, forced expiratory volume in 1 s; IRD relapse-free survival.

(weighted HR (95% CI), 1.50 (1.0 Meier curve of OS is presented in

No significant interactions be the association of FEV1%pred w (all p>0.05), except for BMI (page) mental table 2). The relationship between FEV1 and OS remained consistent in male and high BMI subgroups (figure 3b). The E-value was 1.98, whereas most other risk factors had an HR of 1.21²³ or lower for death, which is considerably smaller than 1.98. This finding suggests that the observed association is unlikely to be attributable to an unmeasured confounder.

Internal validation using bootstrapping confirmed the association between FEV1%pred and OS. The Brier score was 0.12 (95% CI, 0.11 to 0.13), the calibration slope was 0.71 (95% CI, 0.65 to 0.77) and the C-index was 0.55 (95% CI, 0.52 to 0.58), signifying the favourable overall performance of the FEV1%pred and OS regression model (online supplemental table 3).²⁰

DISCUSSION

This study employs the largest sample size to date for examining the relationship between FEV1%pred and OS in individuals with stage I to IIIA NSCLC who have undergone lung resection. Our results demonstrate that decreased FEV1%pred is significantly linked to shorter RFS and OS in operable patients with early-stage NSCLC (online supplemental file 2). These findings suggest that FEV1%pred could be a valuable instrument for evaluating long-term prognosis of individuals with early-stage NSCLC.

There are several debates surrounding the utilisation of FEV1%pred in forecasting the long-term OS in individuals with NSCLC. A notable study by Shen *et al*²⁴ involving patients with advanced-stage NSCLC indicated a strong link between diminished FEV1 and reduced OS. Yet, in the context of early-stage NSCLC, the findings are less consistent. Some investigations, such as those conducted

Protected by copyright, includ Danish patients Bui red serves as a ting long-term ₫ erican patients r uses g results.⁹ This study corroborates the idea that FEV1%pred is a valuſe able method for evaluating the long-term OS in operable lated patients with early-stage NSCLC.

g The utilisation of FEV1%pred as a prognostic marker for patients with NSCLC is further complicated by the absence of a universally accepted threshold value. Normal FEV1%pred values fluctuate based on multiple factors, including age, height, gender, ethnicity and individual health status.²⁵ Conventionally, an FEV1%pred value below 80% has been regarded as reflecting impaired lung function in the general population.²⁶ Furthermore, findings from recent studies have indicated that the cut-off \triangleright values of FEV1%pred for predicting mortality risk in individuals with various health conditions exhibit considerable variability.²⁷ A study by Dittrich *et al*²⁸ recommended continuous updating of the disease- and purpose-specific FEV1 reference values. In the present study, which involved Chinese patients with early-stage NSCLC who underwent lung resection, with a median age of 59 (IQR, 13), we observed that an FEV1 of <82% predicted was associated with a higher all-cause mortality rate. Further research is required to establish the optimal FEV1%pred cut-off value for predicting long-term outcomes in patients with NSCLC of diverse racial, ethnic and age groups.

Recently, there have been considerable advances in studies that have expanded the use of FEV1 for predicting the incidence and recurrence of lung cancer. For instance, a study reported that impaired FEV1 was associated with lung cancer incidence in the general population.²⁹ Likewise, a retrospective analysis published in 2022 identified an association between decreased FEV1 and an elevated risk of worse RFS in a cohort of 151 patients with advanced NSCLC



Figure 2 Kaplan-Meier estimates of the patients with NSCLC with FEV1 <82%pred and FEV1 ≥82%pred (N=775). Kaplan-Meier curves for relapse-free survival (RFS) (a); Kaplan-Meier curves for overall survival (OS) (b). FEV1, forced expiratory volume in 1 s; NSCLC, non-small cell lung cancer. The shadow, along with the curves, represents the 95% CI.

who were treated with immune checkpoint inhibitors.²⁴ Nonetheless, it is important to highlight that a study published in 2014 did not observe any significant correlation between FEV1 and locoregional RFS or distant metastasis-free survival in patients with NSCLC who received postoperative radiotherapy, despite the fact that low FEV1 was notably linked to a poorer 5-year OS.³⁰ The current study supports that FEV1% pred may serve as a valuable instrument for

6

aiding in the prediction of long-term recurrence risk in patients with early-stage NSCLC.

The underlying mechanisms linking FEV1 and the long-term prognosis of patients with NSCLC remain not fully elucidated. Previous studies have suggested that diminished lung function may lead to systemic hypoxia, potentially affecting the efficacy of cancer treatment, such as reduced chemotherapy tolerance.³¹ Patients with impaired FEV1 may have different types



-				
	FEV1<82%pred	FEV1≥82%pred		Weighted HR (95%CI)
All patients	51/234	61/541	••I	1.50 (1.01 to 2.23)
Age				
<60	22/113	29/306	H	1.73 (0.96 to 3.12)
≥60	29/121	32/235	⊢− −1	1.45 (0.84 to 2.53)
Gender				
Female	4/62	17/253 ⊢—	• •	0.76 (0.24 to 2.36)
Male	47/172	44/288	⊢ −−−+	1.58 (1.03 to 2.44)
BMI				
<24	33/130	38/312	• • • • •	1.71 (1.01 to 2.90)
≥24	18/104	23/229	⊢	1.19 (0.62 to 2.29)
Ever smoked				
No	14/108	30/349	⊢	1.22 (0.60 to 2.48)
Yes	37/126	31/192	⊢ i	1.61 (0.96 to 2.68)
				-
		0.125 0.25	0.5 1 2	4
		Favors FEV1<	82%pred Favors FE	V1≥82%pred

Figure 3 Relapse-free survival (a) and overall survival (b) in patient subgroups with FEV1 <82%pred vs FEV1 ≥82%pred. BMI, body mass index; FEV1, forced expiratory volume in 1 s.

of abnormal lung function, which may influence the decision to surgically remove the lung lobes, as well as the deterioration of function after surgery.⁹ It is also plausible that FEV1 decline may reflect tumour biological behaviours. FEV1 levels were linked to the occurrence of lung cancer in a population-based

cohort investigation.³² Furthermore, impaired lung function might influence immune function, leading to a compromised anticancer response.³³ However, it should be noted that these hypotheses are currently speculative and require further investigation to determine the precise mechanisms involved.

LIMITATIONS

This study exhibits several limitations. First, it exclusively enrolled patients who underwent preoperative cardiopulmonary exercise testing, which could introduce selection bias. Second, despite employing the propensity score overlap weighting method and E-value analysis to minimise confounding bias, residual and unmeasured confounding factors may remain. Third, data on neoadjuvant radiotherapy or chemoradiotherapy were not obtained, and data on specific treatment for relapsing patients or the mutation status of the tumours were unavailable, but adjustments were made for factors such as TNM (tumour, node, metastases) classification, accessibility and eligibility for neoadjuvant therapy. Fourth, as RFS and OS are determined by multifaceted conditions, the use of FEV1% pred in a comprehensive preoperative algorithm is necessary to accurately evaluate the risk of relapse and death. Additional research is warranted to ascertain and assess the prognostic significance of combining FEV1%pred with other predictive factors in patients with NSCLC.

CONCLUSION

Reduced preoperative FEV1%pred was significantly associated with worse RFS and OS among operable patients with early-stage NSCLC. The findings suggest that FEV1%pred could be a useful tool for aiding in the prediction and management of long-term recurrence risk in patients with early-stage NSCLC.

Author affiliations

¹Division of Cardiac Rehabilitation, Department of Physical Medicine & Rehabilitation, Xiangya Hospital Central South University, Changsha, Hunan, China ²National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha, Hunan, China

³Department of Neurology, Xiangya Hospital Central South University, Changsha, Hunan, China

⁴Cambridge Respiratory Physiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

⁵Respiratory Physiology, Royal Papworth Hospital, Cambridge, UK

⁶Department of Data Analytics and Application, Ping An Technology, Shanghai, China ⁷Department of Cardiology, Shenzhen District Yantian People's Hospital, Shenzhen, China

⁸Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA

X Karl Sylvester @CambsRespPhys

Contributors SW and SF conceptualised and designed the study. SW, JWR-G, NC, YDu, KS, NX, SF, BY, YDun and SL collected data. SW, JWR-G, NC and YDu analysed the data. SW and JWR-G were responsible for the initial draft of the manuscript. All authors provided comments on earlier drafts of the manuscript, and they all reviewed and approved the final version. YDun, JC and SL are guarantors. SW and SF contributed equally to the work.

Funding This study was supported by the National Natural Science Foundation of China (82172549 to SL, 82272613 to YDun and 82101407 to YDu) and Shenzhen Yantian District Science and Technology Project (YTWS20210101 to JC).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Ethics Committee of Xiangya Hospital, Central South University, reference number 202010145. Given that this research did not impact patient management, the requirement for informed consent was waived by the Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material. BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Suixin Liu http://orcid.org/0000-0001-7621-0096

REFERENCES

- Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc 2019:94:1623-40
- Desai AP, Adashek JJ, Reuss JE, et al. Perioperative Immune 2 Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer. JAMA Oncol 2023;9:135.
- Rajaram R, Huang Q, Li RZ, et al. Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis. Chest 2024;165:1260-70.
- Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009;34:17-41.
- 5 Kakavas S, Kotsiou OS, Perlikos F, et al. Pulmonary function testing in COPD: looking beyond the curtain of FEV1. NPJ Prim Care Respir Med 2021;31:23.
- Oswald NK, Halle-Smith J, Mehdi R, et al. Predicting Postoperative Lung Function Following Lung Cancer Resection: A Systematic Review and Meta-analysis. EClinMed 2019;15:7-13.
- 7 Liang Y, Wang M, Xu X, et al. Reduced Forced Expiratory Volume in 1 Second Percentage Predicted Is Associated With Diffuse Coronary Atherosclerosis in Hospitalized Patients Undergoing Coronary Angiography. Am J Med Sci 2018;355:307-13.
- 8 Heiden BT, Eaton DB Jr, Brandt WS, et al. Development and Validation of the VA Lung Cancer Mortality (VALCAN-M) Score for 90-Day Mortality Following Surgical Treatment of Clinical Stage I Lung Cancer. Ann Surg 2023;278:e634-40.
- technologies 9 Berry MF, Yang C-F, Hartwig MG, et al. Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg 2015;100:271-6.
- 10 Ringbaek T, Borgeskov S, Lange P, et al. Diagnostic and therapeutic process and prognosis in suspected lung cancer. Scand Cardiovasc J 1999;33:337–43.
- Roth K, Nilsen TIL, Hatlen E, et al. Predictors of long time survival 11 after lung cancer surgery: a retrospective cohort study. BMC Pulm Med 2008:8:22
- 12 Song P, Zang RC, Zhang MY, et al. Analysis of prognostic factors for patients with stageIb non-small cell lung cancer after operation. Zhonghua Zhong Liu Za Zhi 2017;39:293–7.
- 13 Dun Y, Olson TP, Li C, et al. Characteristics and reference values for cardiopulmonary exercise testing in the adult Chinese population -The Xiangya hospital exercise testing project (the X-ET project). Int J Cardiol 2021;332:15-21.
- Graham BL, Steenbruggen I, Miller MR, et al. Standardization 14 of spirometry 2019 update. Am J Respir Crit Care Med 2019;200:e70-88.

Protected by copyright, including for uses related to text and data mining, AI training, and similar

Open access

- 15 Çorbacıoğlu ŞK, Aksel G. Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value. *Turk J Emerg Med* 2023;23:195–8.
- 16 Steinvil A, Fireman E, Wolach O, et al. The effect of ethnic origin on pulmonary prediction equations in a Jewish immigrant population. *Respir Med* 2008;102:919–26.
- 17 Zhang Z, Reinikainen J, Adeleke KA, et al. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med 2018;6:121.
- 18 Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res* 2011;46:399–424.
- 19 Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. JAMA 2020;323:2417–8.
- 20 Sanchez-Santos MT, Williamson E, Nicolson PJA, et al. Development and validation of a prediction model for self-reported mobility decline in community-dwelling older adults. J Clin Epidemiol 2022;152:70–9.
- 21 Haneuse S, VanderWeele TJ, Arterburn D. Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies. JAMA 2019;321:602–3.
- 22 Naidoo J, Antonia S, Wu Y-L, et al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol 2023;18:657–63.
- 23 Ochman B, Kiczmer P, Ziora P, et al. Incidence of Concomitant Neoplastic Diseases, Tumor Characteristics, and the Survival of Patients with Lung Adenocarcinoma or Squamous Cell Lung Carcinoma in Tobacco Smokers and Non-Smokers-10-Year Retrospective Single-Centre Cohort Study. *Cancers (Basel)* 2023;15:1896.

- 24 Shen Y-L, Shen C-I, Chiang C-L, et al. Reduced FEV, as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. Front Med (Lausanne) 2022;9:860733.
- 25 Quanjer PH, Stanojevic S, Cole TJ, *et al.* Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012;40:1324–43.
- 26 Rydell A, Janson C, Lisspers K, et al. FEV, and FVC as robust risk factors for cardiovascular disease and mortality: Insights from a large population study. *Respir Med* 2024;227:107614.
- 27 Whittaker HR, Bloom C, Morgan A, et al. Accelerated FEV, decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. *Eur Respir J* 2021;57:2000918.
- 28 Dittrich AS, Dumke M, Kapl F, *et al.* Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany. *Respiration* 2023;102:1.
- 29 Lee HW, Lee H-J, Lee J-K, *et al*. Rapid FEV1 Decline and Lung Cancer Incidence in South Korea. *Chest* 2022;162:466–74.
- 30 Kim H, Lussier YA, Noh OK, et al. Prognostic implication of pulmonary function at the beginning of postoperative radiotherapy in non-small cell lung cancer. *Radiother Oncol* 2014;113:374–8.
- 31 Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Mol Cancer* 2019;18:157.
- 32 Horsfall L, Nazareth I. Respiratory function and the risk of lung cancer in copd patients: a population-based cohort study. ERS International Congress 2016 abstracts; September 2016:A2793.
- 33 Abou Khouzam R, Brodaczewska K, Filipiak A, et al. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. Front Immunol 2020;11:613114.